Cutaneous side effects associated with sunitinib: an analysis of 8 cases

Vignand-Courtin, Claire; Martin, Christine; Beller, Christine Le; Mateus, C.; Barbault-Foucher, S.; Rieutord, André

doi:10.1007/s11096-012-9615-5

Cited by 16 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Generalized erythema, maculopapular or seborrheic dermatitis-like rashes has been reported with sunitinib therapy. Among these manifestations HFSR, genital lesions in the scrotal region and severe stomatitis were the early toxicities which required therapy modifications in the form of dose reduction and discontinuation[78]…”

Section: Pathophysiologymentioning

confidence: 99%

“…In case of grade 2 and grade 3 toxicity, treatment may be interrupted for 7 days and restarted at fifty percent of the dose. Drug related therapies under evaluation by various authors include topical emollients, systemic and topical corticosteroids, tazarotene 0.1percent cream, nicotine patch, vitamin E, pyridoxine, and cycloxygenase-2 (COX-2) inhibitors[8910]…”

Section: Pathophysiologymentioning

confidence: 99%

See 1 more Smart Citation

Sorafenib and sunitinib: A dermatologist′s perspective

Pragasam

Verma

Vasudevan

2014

Indian Dermatol Online J

View full text Add to dashboard Cite

Sorafenib and sunitinib are inhibitors of tumor angiogenesis have recently generated curiosity regarding its role in cutaneous toxicities, which has severely affected the daily activities resulting in interruption or dose modification of therapy in renal cell carcinoma and hepatocellular carcinomas. We discuss the pathophysiology, adverse cutaneous effects and their grading, potential high risk factors, role of gene polymorphism, critical period of hand-foot skin reaction development and their management.

show abstract

Section: Pathophysiologymentioning

confidence: 99%

Section: Pathophysiologymentioning

confidence: 99%

Sorafenib and sunitinib: A dermatologist′s perspective

Pragasam

Verma

Vasudevan

2014

Indian Dermatol Online J

View full text Add to dashboard Cite

show abstract

“…Sunitinib genel olarak iyi tolere edilen bir ilaçtır. Ciddi yan etki insidansı oldukça düşüktür (6). Sunitinibe bağlı gelişen kutanöz yan etkiler içinde klinik açıdan en önemlisi ve en sık görüleni el ayak deri reaksiyonudur (4).…”

Section: Discussionunclassified

Hand Foot Skin Reaction Associated with Sunitinib

Cemil¹,

Akış²,

Canpolat³

et al. 2015

tdd

View full text Add to dashboard Cite

Sunitinib renal hücreli karsinom ve gastrointestinal stromal tümörlü hastalarda yarar gösteren bir multikinaz inhibitörüdür. Sunitinib pek çok kutanöz toksisiteye yol açmaktadır. El ayak deri reaksiyonu en karakteristik ve en sık görülen kutanöz toksisitedir. Lezyonlar iyi sınırlı, özellikle basınç alanlarına lokalize ve çevresi eritem ile sınırlı sarı, ağrılı kallus benzeri hiperkeratoz ile karakterizedir. Elli dört yaşında erkek hasta renal hücreli karsinom nedeniyle başlanan 50 mg/gün oral sunitinib tedavisinin yirminci gününde el ve ayakta ağrılı döküntüleri gelişmesi nedeniyle polikliniğimize başvurdu. Dermatolojik muayenesinde avuç içi ve ayak tabanlarında çok sayıda sarı renkli, çevresi eritemli halo ile çevrili hiperkeratotik plakları mevcuttu. Hastaya tanımlayıcı klinik bulguları nedeniyle sunitinibe bağlı el ayak deri reaksiyonu tanısı kondu. El ayak deri reaksiyonu hastaların yaşam kalitesini ve tedavi dozlarını oldukça etkilemektedir. El ayak deri reaksiyonunun erken tanısı ve tedavisi ilaçtan kazanılacak maksimum etkinin sağlanmasında hayati önem taşımaktadır. Anahtar kelimeler: Antineoplastik ajanlar, El ayak sendromu, ilaç erüpsiyonu, renal hücreli karsinom, sunitinib, yan etkiler Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemiştir. Bengü ÇevirgenCemil, Havva Kaya Akış, Filiz Canpolat, Müzeyyen Gönül, Seda Atay, Gökşen İnanç İmamoğlu* Sunitinib ile İlişkili El Ayak Deri ReaksiyonuHand Foot Skin Reaction Associated with SunitinibSunitinib is a multi-targeted kinase inhibitor showing benefits in patients with renal cell carcinoma, and gastrointestinal stromal tumor. Sunitinib may cause various cutaneous toxicities. The most characteristic and common cutaneous toxicity is hand-foot skin reaction. Lesions are characterized by yellow painful callus like hyperkeratosis surrounded by a rim of erythema, they are well-demarcated and localized especially over pressure areas. A 54-year-old male patient with a history of renal cell carcinoma developed painful eruption twenty days after oral sunitinib had been started on 50 mg daily. Dermatological examination showed multiple, yellow, hyperkeratotic plaques with erythematous halos on palms, and soles. The patient was diagnosed as hand-foot skin reaction due to sunitinib due to descriptive clinical findings. Hand-foot skin reaction can greatly affect patients' quality of life and treatment dosages. Early diagnosis and timely treatment of hand-foot skin reaction will be vital to ensure maximum potential of these drugs.

show abstract

“…noticed that SH occur during the first 2 months of treatment and are associated with a hand‐and‐foot skin reaction, facial erythema, scalp dysesthesia, and alopecia . Associated adverse skin effects rarely require any dose reduction, and include genital lesions, cutaneous eruption, hand‐and‐foot syndrome, yellow discoloration of the skin, hair depigmentation, xerosis, pigmented lesions, vascular lesions, erythema, facial edema, and pruritus …”

Section: Etiologiesmentioning

confidence: 99%

Splinter hemorrhages of the nails: a systematic review of clinical features and associated conditions

et al. 2016

View full text Add to dashboard Cite

Splinter hemorrhages (SHs) of the nails represent a frequent although not specific clinical finding that has been associated with conditions of varying severity. However, to date, there is no single report of their characteristics and etiologies. The aim of this study is to guide clinical practice by reviewing all of the data concerning SH of the nails that have become available since the first description of this condition was published in 1923, with particular reference to all clinical features, associated medical conditions, pathogenesis, and necessary workup. PubMed and EMBASE were searched using the keywords "splinter" AND "hemorrhage*"; the only articles excluded were those studying SHs of the retina. Splinter hemorrhage is a frequent nail disorder that may be idiopathic, drug-induced, or a sign of a dermatological disease, such as psoriasis and lichen planus, or a wide range of systemic disorders, the most important of which are infections and vasculitis. Clinicians and dermatologists should be aware of all the clinical features of both SH and associated medical conditions.

show abstract

Cutaneous side effects associated with sunitinib: an analysis of 8 cases

Cited by 16 publications

References 8 publications

Sorafenib and sunitinib: A dermatologist′s perspective

Sorafenib and sunitinib: A dermatologist′s perspective

Hand Foot Skin Reaction Associated with Sunitinib

Splinter hemorrhages of the nails: a systematic review of clinical features and associated conditions

Contact Info

Product

Resources

About